| 23.37 Delayed Data As of Sep 16 |  +0.13 / +0.56%Today’s Change | 17.20 Today|||52-Week Range 28.45 | +26.53% Year-to-Date |
| Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment Sep 13 / Zacks.com - Paid Partner Content | Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study Sep 04 / Zacks.com - Paid Partner Content |
| Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report? Sep 05 / Zacks.com - Paid Partner Content |
| Previous close | 23.24 |
| Today’s open | 23.33 |
| Day’s range | 23.16 - 23.53 |
| Volume | 2,299,079 |
| Average volume (3 months) | 3,315,667 |
| Market cap | $8.2B |
| Earnings growth (last year) | -272.12% |
| Earnings growth (this year) | +4.96% |
| Earnings growth (next 5 years) | +0.84% |
| Revenue growth (last year) | -3.94% |
| P/E ratio | NM |
| Price/Sales | 0.77 |
| Price/Book | 2.98 |
| Today’s change | Today’s % change | |
|---|---|---|
| CTLTCatalent Inc | -0.77 | -1.50% |
| JAZZJazz Pharmaceuticals... | +2.60 | +1.98% |
| SRPTSarepta Therapeutics... | +1.02 | +1.19% |
| PRGOPerrigo Company PLC | +0.74 | +1.32% |
| Next reporting date | October 23, 2019 |
| EPS forecast (this quarter) | $1.07 |
| Annual revenue (last year) | $8.4B |
| Annual profit (last year) | -$4.1B |
| Net profit margin | -49.50% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman & Chief Executive Officer Joseph C. Papa |
Chief Financial Officer & Executive Vice President Paul S. Herendeen |
Corporate headquarters Laval, Quă©bec |
